Brazil’s Spiraling Access Suits And The Potential Impact On Companies
Spending on medicines as a result of litigation against health authorities is soaring in Brazil. Scrip investigates the challenges firms may face in future, including greater pricing pressure, a more NICE-like health technology appraisal system and increased scrutiny over any perceived industry wrongdoing.
You may also be interested in...
As Brazil turns to risk sharing agreements to improve access to expensive treatments, the health ministry has its eye on Biogen’s rare disease treatment Spinraza (nusinersen).
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.